These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. Di Lieto A; De Falco M; Pollio F; Mansueto G; Salvatore G; Somma P; Ciociola F; De Rosa G; Staibano S J Soc Gynecol Investig; 2005 Feb; 12(2):123-8. PubMed ID: 15695108 [TBL] [Abstract][Full Text] [Related]
7. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). Mizutani T; Sugihara A; Nakamuro K; Terada N J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry of vascular changes in leuprolide acetate-treated leiomyomas. Mesia AF; Gahr D; Wild M; Mittal K; Demopoulos RI Am J Obstet Gynecol; 1997 May; 176(5):1026-9. PubMed ID: 9166163 [TBL] [Abstract][Full Text] [Related]
9. Absence of a dose-response effect of leuprolide acetate on leiomyomata uteri size. Kiltz RJ; Rutgers J; Phillips J; Murugesapillai ML; Kletzky OA Fertil Steril; 1994 Jun; 61(6):1021-6. PubMed ID: 8194611 [TBL] [Abstract][Full Text] [Related]
10. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment. Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148 [TBL] [Abstract][Full Text] [Related]
12. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas. Rein MS; Barbieri RL; Welch W; Gleason RE; Caulfield JP; Friedman AJ Obstet Gynecol; 1993 Dec; 82(6):901-5. PubMed ID: 8233262 [TBL] [Abstract][Full Text] [Related]
13. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas. Cramer SF Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847 [No Abstract] [Full Text] [Related]
14. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor. De Falco M; Staibano S; D'Armiento FP; Mascolo M; Salvatore G; Busiello A; Carbone IF; Pollio F; Di Lieto A J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947 [TBL] [Abstract][Full Text] [Related]
15. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7. Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260 [TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890 [TBL] [Abstract][Full Text] [Related]
17. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14). Takahashi K; Kawamura N; Ishiko O; Ogita S Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889 [TBL] [Abstract][Full Text] [Related]
18. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Friedman AJ; Daly M; Juneau-Norcross M; Rein MS Fertil Steril; 1992 Aug; 58(2):413-5. PubMed ID: 1633911 [TBL] [Abstract][Full Text] [Related]